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Abstract 
Decision-making in pituitary disease is critically dependent on high quality imaging of the 
sella and parasellar region. Magnetic resonance imaging (MRI) is the investigation of choice 
and, for the majority of patients, combined T1 and T2 weighted sequences provide the 
information required to allow surgery, radiotherapy (RT) and/or medical therapy to be 
planned and long-term outcomes to be monitored. However, in some cases standard clinical 
MR sequences are indeterminate and additional information is needed to help inform the 
choice of therapy for a pituitary adenoma (PA). This article reviews current 
recommendations for imaging of PA, examines the potential added value that alternative MR 
sequences and/or CT can offer, and considers how the use of functional/molecular imaging 
might allow definitive treatment to be recommended for a subset of patients who would 
otherwise be deemed unsuitable for (further) surgery and/or RT. 
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Introduction 
 
Although almost always benign, pituitary adenomas (PA) can be associated with significant 
morbidity and even increased mortality by virtue of hormone hypersecretion (e.g. 
acromegaly, Cushing syndrome), hypopituitarism, and local mass effects (e.g. visual loss 
due to chiasmal compression). Recent studies indicate a prevalence rate that is 3.5 to 5-
times higher than previously suspected, with clinically-apparent tumours affecting between 
1:1000 and 1:1500 of the general population(1). It is possible this still represents an under-
estimate bearing in mind up to 14.4% (in autopsy studies) and up to 22.5% (in radiologic 
studies) of the population have been reported to have a pituitary abnormality, but not all of 
these undergo formal endocrine assessment(2). 
 
In recent years, the repertoire of medical therapies available for the management of pituitary 
tumours has increased significantly [e.g. the advent of GH receptor (GHR) antagonist or 2nd 
generation somatostatin receptor ligand (SRL) therapy for acromegaly](3). In addition, 
modern radiotherapy techniques (including stereotactic radiosurgery) allow for more precise 
targeting of a pituitary adenoma while sparing surrounding structures. However, for many 
patients pituitary surgery remains an important, often first, step in their management (either 
with curative intent or to reduce tumour bulk and facilitate more effective adjunctive 
treatment). Good quality imaging of the sella and parasellar regions is therefore critical to 
decision-making, even when surgery and/or radiotherapy are not recommended. For most 
patients, this means undergoing dedicated pituitary magnetic resonance (MR) imaging 
(MRI), which provides important information about the adenoma itself and key surrounding 
structures. In a small number of cases, pituitary computed tomography (CT) is required 
(most commonly when MRI is not possible/tolerated). However, while MRI and/or CT provide 
sufficient information for the management of the majority of cases, routine clinical sequences 
do not always reliably identify the site of de novo, persistent or recurrent adenoma, which in 
turn may reduce the opportunity for curative surgery and/or radiotherapy (RT). 
 Accordingly, several groups have explored the potential utility of using alternative MR 
sequences to inform the management of different pituitary tumour subtypes. In addition, we 
and others have examined the role(s) of functional imaging (e.g. using molecular PET 
tracers), in combination with MRI, to allow more accurate localisation of the site(s) of PA. 
This article provides an update on current approaches to imaging in pituitary adenomas, 
reviews possible indications for adopting specific MR (and/or CT) sequences and considers 
how advances in molecular PET imaging might be used to improve patient outcomes from 
targeted therapies such as (repeat) transsphenoidal surgery (TSS) or stereotactic 
radiosurgery (SRS). 
  
Magnetic Resonance Imaging  
 
MRI is the preferred cross-sectional imaging modality for identifying lesions within the 
pituitary gland and surrounding parasellar region, and provides a high detection accuracy(4–
6). When requesting a pituitary MR scan, several factors should be taken into account 
(Table 1).   
 
Insert Table 1 here 
 
The normal anterior pituitary gland is isointense to grey matter on non-contrast T1 and T2 
weighted standard Spin Echo (SE) sequences (Fig. 1a,b,e,f), while the posterior pituitary has 
intrinsic high T1 signal (Fig. 1b) but is hypointense on T2. Following contrast injection, the 
infundibulum and gland progressively enhance (Fig. 1c,d); however, contrast uptake by 
pituitary adenomas is typically slower, giving rise to delayed enhancement and washout 
characteristics, which can help to reveal an otherwise poorly visualised microadenoma (Fig. 
2a). Gadolinium, a naturally-occurring lanthanide, is the most commonly employed contrast 
agent during pituitary imaging. It is particularly suited for use as an MRI contrast agent 
because it has seven unpaired electrons which confer strong paramagnetic properties. In its 
free form Gadolinium is toxic and it must therefore be chelated to a carrier ligand to allow 
clinical use. Gadolinium-based contrast agents (GBCAs) can be divided in to four groups 
according to whether the carrier ligand is linear or macrocyclic and ionic or non-ionic. In 
recent years concern has been raised regarding the safety of GBCAs, and the pituitary 
community has been alerted to the potential for long-term central nervous system retention 
even in patients with normal renal function, which is particularly relevant given the need for 
many pituitary patients to continue with long-term imaging surveillance(7). Macrocyclic 
GBCAs exhibit greater chemical stability than their linear counterparts, and this has been 
linked to a lower risk of nephrogenic systemic fibrosis and reduced gadolinium tissue 
deposition; however, they appear to carry a higher risk of allergic reactions, albeit still 
relatively rare. Therefore, while GBCAs continue to play an important role in imaging of the 
sella and parasellar region, it is important to consider when contrast might not be required 
[e.g. when T1 non-contrast and/or T2 sequences alone can provide sufficient information to 
inform management (see below)], thereby minimising exposure(8). 
 
Insert Figure 1 here 
 
Another important consideration when imaging the sella is the choice of magnetic field 
strength. 1.5T SE MRI is still commonly used in routine clinical practice and provides 
reasonable spatial resolution to permit 2.0 mm or 3.0 mm slice thickness. However, very 
small microadenomas (e.g. Cushing, thyrotropinoma) may escape detection, although this 
risk can be partially mitigated by careful selection of the T1 SE parameters(9). In recent 
years, higher field strength MRI systems (3T and more latterly 7T) have become available, 
providing higher signal to noise ratio with a reduction in acquisition time, and allowing 1.0 
mm sections to be performed(10–12). Therefore, while 1.5T SE MRI is a reasonable option 
in the first instance, for those patients with suspected microadenomas but with equivocal or 
‘negative’ 1.5T scans, referral for a 3T study should be considered(13). However, it remains 
to be seen whether using 7T MRI brings sufficient additional benefits to outweigh potential 
challenges such as the identification of a greater number of incidental pituitary abnormalities. 
 
In routine clinical practice, most PA are readily visualised on T1 and T2 weighted MRI which 
provide important information about the size of the lesion [micro- (<1cm) versus macro- 
(³1cm) adenoma] and the degree of parasellar involvement (Fig. 2). Several approaches 
have been proposed to define the extent of lateral extension and cavernous sinus invasion, 
with the most commonly used being the Knosp classification(14). As a general rule, the 
higher the grade, the greater the degree of cavernous sinus involvement, and the lower the 
probability of achieving full surgical remission. The inclusion of Grades 3A and 3B 
differentiates between the different outcomes for adenomas invading the superior and the 
inferior cavernous sinus compartments (Fig. 2d)(15). 
 
Insert Figure 2 here 
 
Dynamic contrast-enhanced MRI (based on T1 weighted images obtained pre-and 
immediately following gadolinium injection) (Table 1) may be indicated when standard 
sequences have failed to identify a pituitary lesion but clinical features strongly suggest the 
presence of an adenoma, for example in suspected Cushing disease due to an ACTH-
secreting microadenoma(5,16). However, gradient echo [e.g. spoiled gradient echo (SGE) / 
(fast) spoiled gradient recalled echo (FSPGR/SPGR)] has been reported to offer greater 
sensitivity for detecting corticotroph microadenomas with only occasional cases detected on 
dynamic but not gradient echo MRI(16). Strategies such as the administration of 
corticotrophin-releasing hormone immediately prior to scanning have not provided 
convincing evidence of an additional benefit(13). 
 
Recently, there has been a resurgence of interest in the potential added value that T2 
sequences can offer when assessing pituitary lesions – in particular, offering diagnostic 
insights that are not deducible from T1 sequences, and also potentially sparing the need for 
contrast enhanced imaging in some patients (thus reducing GBCA exposure – see above). 
Jean-François Bonneville has elegantly made the case for increased use (and reporting in 
the literature) of T2 MR findings in several pituitary disorders, and these are summarised in 
Table 2(8). 
 
Insert Table 2 here 
 
An array of alternative MR sequences, which are routinely employed in other clinical 
contexts, have also been tried in several pituitary disorders with mixed results (Table 3). 
Although several have shown potential promise, for the most part findings need confirmation 
in larger cohorts before they can be recommended for routine clinical use.  
 
Insert Table 3 here 
 
Computed tomography (CT) 
 
Modern computed tomography (CT) is a reasonable substitute where MRI is contraindicated 
(including in patients with non-MR compatible pacemakers/cardiac devices, vascular clips or 
metallic foreign bodies) or when the patient declines MRI (e.g. due to claustrophobia). 
Reasonable evaluation of pituitary macroadenomas is possible with dedicated pituitary CT 
(Fig. 3a), but it is generally less informative for the assessment/detection of small tumours, 
although advanced CT techniques (e.g. dynamic contrast-enhanced multisection CT) have 
been trialled and may even aid the detection of conventional MR imaging-occult pituitary 
microadenomas(17). 
 
Even when MRI is possible, there are several situations in which CT can provide useful 
additional information regarding a sella-based or parasellar lesion. These include 
identification of bone destruction (e.g. by an invasive macroprolactinoma) (Fig. 3b) and 
confirmation of suspected intra/parasellar calcification [e.g. calcified PA (with thyrotropinoma 
being the classic example) or craniopharyngioma] (Fig. 3c). CT is also used in conjunction 
with MRI to facilitate radiotherapy planning and may reveal previously unsuspected tumour 
invasion of bony structures(18,19). 
 
Insert Figure 3 here 
 
 
Functional Pituitary Imaging 
 Despite recent advances in cross-sectional imaging, there remain several situations in which 
clinical decision-making is limited by indeterminate MRI and/or CT findings, including: 
(i) small PA that cannot be readily visualised even using a combination of sequences (e.g. 
corticotroph adenomas may evade detection in 30-40% of patients with Cushing 
disease(20); similarly, thyrotroph and lactotroph tumours are not always easily localised) 
(ii) following primary intervention (surgery, radiotherapy or medical therapy) when post-
treatment change may be difficult to distinguish from residual functioning tumour 
(iii) in the presence of a confounding pituitary incidentaloma 
 
Functional imaging represents an alternative and complementary approach to traditional 
anatomical imaging and has found widespread use in many endocrine disorders [e.g. 
technetium-99m-pertechnetate and technetium-99m-sestamibi scintigraphy in 
hyperthyroidism and hyperparathyroidism respectively; 123I-metaiodobenzylguanidine (123I-
MIBG) scintigraphy for detection of phaeochromocytoma/paraganglioma]. However, while 
scintigraphy remains a useful clinical technique, especially when combined with single 
photon emission computed tomography (SPECT) for image acquisition, its application in 
other fields of endocrinology has been limited by its modest sensitivity for detecting small 
lesions.  
 
Positron emission tomography (PET) offers a solution to this problem and can be combined 
with CT (PET/CT) or MRI (PET/MR) to allow detection of even subcentimetre lesions. The 
development of PET ligands targeting different cellular processes (e.g. glucose or amino 
acid uptake, receptor or intracellular enzyme expression) has opened up new opportunities 
for the application of PET in endocrine disorders. The potential superiority of PET over 
conventional scintigraphy is exemplified by the comparison of 111Indium-pentetreotide 
scintigraphy (± SPECT) (‘octreoscan’) and 68Gallium-DOTATATE PET/CT for the 
investigation of neuroendocrine tumours (NET), where the latter often detects lesions not 
seen on a conventional octreoscan(21).  
 
To date, functional imaging has found limited use in the routine management of pituitary 
adenomas, although several groups have explored various modalities including somatostatin 
receptor scintigraphy (SRS) or PET, 18F-fluorodeoxyglucose (18F-FDG)-PET and 11C-
methionine(11C-Met)-PET.  
 
Somatostatin Receptor Scintigraphy and PET 
Somatostatin receptors (SSTRs) are expressed in normal human pituitary tissue and, to 
varying degrees, in different subtypes of pituitary adenoma. For example, somatostatin 
receptor subtype 2 (SSTR2) is detectable in most somatotroph adenomas, whereas SSTR5 
expression is more variable(22). In contrast, corticotroph adenomas express higher levels of 
SSTR3 and SSTR5, but have also recently been confirmed to express SSTR2A(23). The 
use of Somatostatin Receptor Scintigraphy (e.g. 111Indium-pentetreotide) in the investigation 
and management of PA is therefore confounded by several factors: background uptake by 
normal pituitary tissue; dependence on SSTR subtype expression of the tumour; and limited 
spatial resolution and sensitivity of scintigraphy, even when combined with SPECT. 68Ga-
DOTATATE PET has the potential to address the latter, but it has yet to find clear utility in 
the management of PA, although preliminary data suggests that combination with 18F-FDG 
PET may allow distinction of normal gland and adenoma in some cases of primary and 
recurrent disease(24,25). 
 
18F-FDG PET 
The literature contains numerous case reports of incidentally-detected 18F-FDG uptake by 
pituitary adenoma(26–29). In contrast, in a large retrospective analysis of incidental pituitary 
uptake in >40,000 patients who had undergone whole body FDG PET/CT, the overall 
incidence was just 0.073%(30). Together these findings (demonstrable uptake by PA with a 
negligible false positive rate) suggest a possible role for 18F-FDG PET in pituitary imaging. 
Indeed, the potential utility of 18F-FDG PET has been explored in various subtypes of 
PA(24,25). but has been most extensively studied in the context of corticotroph tumours, 
which often evade detection on MRI. However, findings have been largely disappointing. In a 
prospective study of ten consecutive patients with subsequently confirmed CD, high 
resolution 18F-FDG PET (18F-FDG hrPET) was performed together with SE and SPGR 
MRI(31). 18F-FDG hrPET revealed increased tracer uptake in four patients, two of whom had 
no demonstrable lesion on SE MRI. However, SPGR proved more sensitive than 18F-FDG 
hrPET, identifying a pituitary adenoma in seven cases and, importantly, no adenomas were 
detected by 18F-FDG hrPET that were not visualised on SPGR MRI. A comparable detection 
rate (58%) was reported by Alzahrani and colleagues in their retrospective study of 12 
patients who underwent conventional 18F-FDG PET/CT(32). Accordingly, 18F-FDG PET has 
yet to find a place in the routine management of PA. 
 
11C-methionine PET 
Several groups have demonstrated the potential utility of 11C-methionine PET/CT (Met-
PET/CT) in different pituitary tumour subtypes, both for the localisation of de novo tumours, 
especially microadenomas, and also for the identification of persistent or recurrent 
disease(18,33–36). However, a key limitation of Met-PET/CT is the relative lack of 
anatomical detail provided by CT when compared with MRI. This has led us and other 
workers to explore the possibility of fusing functional images derived from PET-CT with 
cross-sectional images obtained during volumetric MRI (e.g. FSPGR MRI)(35–38). In this 
way, the precise site(s) of 11C-methionine uptake can be delineated through coregistration of 
PET/CT and MRI images. With the advent of PET/MR this process will become even easier 
and more convenient, as has been demonstrated with other tracers(25).  
 
However, several important considerations must be taken in to account when developing a 
specialist pituitary imaging service using 11C-methionine PET. 
 
Patient selection and preparation 
Careful case selection is important. The majority of patients with PA do not require molecular 
imaging. However, the ability to correlate structure with function is potentially useful when 
either a small de novo functioning tumour (e.g. in Cushing disease, thyrotropinoma, 
prolactinoma or, less commonly, acromegaly), or residual/recurrent functioning PA (e.g. 
acromegaly) cannot be reliably identified on good quality MRI, and when definitive treatment 
(TSS or SRS) would otherwise be considered. As molecular imaging with 11C-methionine 
depends on the presence of functioning adenoma tissue, it is important to ensure adequate 
washout of agents that might otherwise suppress hormone production by the tumour [e.g. 
SSA or dopamine agonist (DA) therapy in acromegaly], and to confirm active disease prior to 
imaging. We recommend discontinuation of short-acting SSA therapy (i.e. octreotide) and 
DA at least one month prior to scanning. For depot SSA (e.g. Sandostatin LARÒ or 
Lanreotide AutogelÒ) a longer washout period is required (typically 3 months). Patients 
should be instructed to fast for at least 4 hours before the scan. On the day, a further 
assessment of disease activity [paired random GH and IGF-1 in acromegaly; paired 9am 
adrenocorticotrophic hormone (ACTH) and cortisol followed by late night salivary cortisol in 
Cushing syndrome; paired free thyroxine and TSH in thyrotropinoma; prolactin in 
prolactinoma], together with assessment of remaining pituitary function, should be 
undertaken.  
 
Tracer production 
Carbon-11 (11C) has a half-life of just 20 minutes and is synthesised using a particle 
accelerator (Cyclotron). Following production, several quality control steps (identification, 
purity, stability, half-life confirmation, pH detection and substance sterility) must be completed 
before the tracer can be administered(39). The short half-life therefore limits its use to centres 
with an in-house cyclotron. Typically, between 100 and 400 MBq is administered 
intravenously. 
 
PET acquisition  
Uptake time is typically standardised (e.g. 20 min) following tracer injection. Acquisition of 
low dose CT images allows for attenuation correction (AC) of the PET dataset. A similar 
approach is required for hybrid PET/MR systems(40–43). 
 
PET/CT-MRI coregistration 
11C-methionine PET/CT coregistration to independently acquired MRI (Met-PET-MRICR) can 
be performed using commercially available image fusion software. Amongst the most 
commonly used are automated (e.g. GE Xeleris®) and manual (e.g. MedCom Prosoma® and 
Slicer®) systems(44–46). Volumetric (1mm thickness) MRI facilitates coregistration. 
 
11C-methionine PET/CT-MRI findings in different PA subtypes  
 
Prolactinoma 
Lactotroph PA generally demonstrate avid 11C-methionine uptake (up to 9 times background 
brain uptake). In patients with hyperprolactinaemia for whom medical therapy with DA is not 
tolerated or advised, and in whom pituitary MRI is indeterminate, Met-PET-MRICR can 
facilitate localisation of the tumour to guide selective TSS (Fig. 4). Similarly, in drug resistant 
macroprolactinomas the site(s) of residual disease can be readily localized to help the 
pituitary multidisciplinary team decide whether surgery or RT is appropriate (Bashari, 
Koulouri and Gurnell, unpublished data). 
 
 Insert Figure 4 here 
 
Acromegaly 
Similar to lactotroph tumours, somatotropinomas avidly take up 11C-methionine and Met-
PET-MRICR can help distinguish metabolically active residual/recurrent PA from scar 
tissue(36). As indicated above, certain types of medical therapy (e.g. SSA, DA) can diminish 
tracer uptake and appropriate washout should be completed before imaging is 
performed(36).  
 
Insert Figure 5 here 
 
Cushing disease 
11C-methionine uptake by corticotroph adenomas is typically less than is seen in other 
pituitary tumour subtypes. Possible reasons for this include the relatively low representation 
of corticotrophs amongst anterior pituitary cells (10-20%); their localization in the centre of 
the gland (leading to additional challenges due to tumoral tracer uptake merging with that of 
the normal gland); in addition, the periodic/cyclical nature of ACTH production in some 
corticotroph tumours may result in low uptake if the patient is scanned when the tumour is 
relatively quiescent (hence the need to confirm active disease at the time of imaging). 
Accordingly, success rates for localizing de novo or recurrent corticotroph tumours are of the 
order of ~70% (Fig. 6).  
 
Insert Figure 6 here 
 
TSH-secreting PA (thyrotropinoma) 
The majority of thyrotroph tumours demonstrate avid uptake of 11C-methionine (Fig. 7). We 
have also shown that this uptake can be suppressed by SSA therapy, thus providing an 
‘endocrine switch’ which can offer added reassurance when MR findings are unconvincing 
for the presence of an adenoma(37). 
 Insert Figure 7 here 
 
Clinically non-functioning pituitary adenoma / gonadotropinoma 
Clinically non-functioning PAs (NFPA) and functioning gonadotropinomas also demonstrate 
significant 11C-methionine uptake which can therefore be used as a biomarker of 
residual/recurrent disease (Fig. 8). 
 
Insert Figure 8 here 
 
Reassuringly, 11C-methionine uptake by cystic pituitary lesions within the sella is typically 
low/absent when compared with the normal background pituitary tissue or a PA (Fig. 9). 
 
Insert Figure 9 here 
 
 
 
  
Summary 
In the majority of cases when pituitary imaging is indicated, good quality T1 (± contrast 
enhancement) and T2 weighted sequences will provide sufficient information to allow 
effective clinical decision making. For those patients in whom MRI findings are inconclusive, 
consideration should be given to the use of other MR sequences, but these should only be 
requested following discussion with the pituitary multidisciplinary team (MDT). When MRI is 
not possible or tolerated, thin slice pituitary CT is a reasonable alternative, while in other 
situations it can augment the findings from MRI (e.g. when bony invasion/destruction is 
suspected). Although functional imaging with molecular PET tracers (e.g. 11C-methionine) is 
unlikely to find widespread usage, emerging evidence suggests that in a subgroup of 
patients it may play an important role in facilitating (further) definitive intervention (e.g. TSS 
or RT), thereby sparing patients and healthcare systems the need for long-term, often 
expensive, medical therapy. The establishment of a small number of centres with expertise 
in molecular pituitary imaging may sit comfortably with the recently proposed model for 
Pituitary Tumor Centres of Excellence (PTCOE)(47).  
 
Practice Points 
• All clinicians involved in the management of pituitary patients should have a good 
understanding of the MR sequences that are routinely used for pituitary imaging in their 
centre and when to consider alternative MR protocols. 
• The decision to request gadolinium-enhanced MR sequences (e.g. T1 weighted with 
contrast) should include careful consideration of recent concerns raised regarding 
gadolinium deposition with GBCAs – if in doubt then discuss with the pituitary MDT and 
consider the use of alternative sequences (e.g. T2 weighted).  
• Pituitary CT is indicated when MRI is not possible or tolerated, and when there is concern 
regarding bone invasion/destruction or intratumoral calcification. 
• Functional imaging with the molecular tracer 11C-methionine (Met-PET-MRICR) can help 
identify de novo or residual/recurrent PA in all tumour subtypes when MRI findings are 
inconclusive. 
 
Research Agenda 
• It remains unclear whether the advent of MR scanners with increased magnetic field 
strength (e.g. 7T) will bring added benefits that outweigh the potential disadvantages of 
identifying a greater proportion of confounding incidental pituitary lesions. Further studies 
are awaited. 
• Although several MRI protocols that find routine use in other clinical settings (e.g. DWI, 
Elastography) have been applied to pituitary imaging with promising results, further 
studies are needed to determine whether these should be adopted in to routine clinical 
practice. 
• Functional imaging with the molecular tracer 11C-methionine (Met-PET-MRICR or Met-
PET/MRI) shows significant promise for producing a step change in the management of a 
subgroup of patients with PA. However, challenges remain when handling the raw 
datasets and collaborative studies drawing on the expertise of colleagues in the applied 
sciences (mathematics, physics) will likely be required to take image analysis to the next 
level. 
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Table 1. Points to consider when requesting a pituitary MRI protocol 
 
Key questions Options / examples 
Which sequences? 
 
Spin Echo (SE) / Fast Spin Echo (FSE): 
- T1 weighted1,2  
- T2 weighted  
- proton density (PD) weighted2 
 
Gradient Echo (GE): 
- spoiled gradient echo (e.g. to permit thinner slices through the sella – see below) 
 
Other: 
- Diffusion weighted (DWI) 
- Perfusion weighted (PWI) 
- Inversion recovery (IR) 
- Fluid attenuation inversion recovery (FLAIR) 
- Magnetic resonance angiography (MRA) 
With or without contrast enhancement? Gadolinium1 
Which planes? Coronal; sagittal; axial 
Which slice thickness? Standard 2-3 mm; volumetric (e.g. consecutive 1 mm) 
Which magnetic field strength? 1.5T, 3T, 7T 
 
Key: 1T1 weighted MRI following contrast may also include (i) dynamic sequences [images obtained from multiple locations throughout the gland at multiple time points (e.g. 
0, 30, 60, 90, 120 and 180 seconds) to help identify microadenomas (which exhibit delayed enhancement) or distinguish residual/recurrent tumour from postoperative change], 
and (ii) delayed sequences (to assess the cavernous sinuses and characterize other sella/parasellar tumours); 2Fat suppressed T1 or PD sequences may improve 
visualization of the posterior pituitary gland by suppressing signal from adjacent clival bone marrow. 
Table 2. Specific indications for T2 weighted pituitary MRI – according to Bonneville(8) 
 
 
Indication T2 weighted MRI findings References 
 
Suspected microprolactinoma - potential to obviate 
requirement for gadolinium injection 
 
Hyperintense (8) 
 
Identification of silent corticotroph macroadenomas – with 
differentiation from non-functioning PA 
 
Microcystic pattern (in >50% of cases) (8,48) 
 
Investigation of GH-secreting PA: 
- prediction of response to first generation SSA therapy 
- identification of invasion of the medial wall of the 
cavernous sinus 
 
 
Hypointense [commoner (>50%)]: smaller tumours with less CSI, 
which correspond to densely granulated tumours; good 
response to SSA 
 
Isointense / hyperintense: larger, typically more invasive 
tumours; less SSA responsive 
 
(8,49,50) 
Diagnosis of hypophysitis 
 
Hyperintense (even when overall size of gland is within normal 
limits) 
 
(8) 
Diagnosis of Rathke’s cleft cyst Hypointense (8) 
 
Key: CSI, cavernous sinus invasion; PA, pituitary adenoma; SSA, somatostatin analogue therapy 
  
Table 3. Alternative MR sequences that have been applied in the investigation of pituitary disorders 
 
MRI sequence Features Potential application(s) in pituitary disorders References 
Diffusion weighted  
(DWI) 
 
Measures the diffusion of water molecules in 
biological tissues; most commonly used to 
detect cytotoxic oedema in the context of acute 
cerebral ischaemia/infarction 
 
Detection of acute pituitary apoplexy/infarction 
 
Distinguishing intra-/supra-sellar cystic lesions 
(51) 
 
(52) 
Apparent Diffusion  
Coefficient (ADC) A subtype of DWI 
 
Prediction of the consistency of PA pre-surgery:  
- some authors have reported a reduced ADC 
with increasing collagen content 
- others have found no relation between ADC 
and tumour consistency 
 
 
 
 
(53–55) 
 
(56–58) 
Diffusion Tensor  
(DTI) 
An extension of DWI which analyses the 
directional diffusion of water molecules in 
biological tissue 
 
Optic nerve tractography to inform treatment 
planning and predict likelihood of visual recovery 
following transsphenoidal surgery 
 
(59–61) 
Perfusion weighted 
(PWI) Assesses tissue perfusion at the capillary level 
 
Assessment of the vascularity of PA pre-surgery 
 
Identification of other vascular lesions (e.g. 
meningioma) which may be mistaken for a PA 
 
(62) 
 
 
(63,64) 
Magnetic 
Resonance 
Angiography (MRA) 
Provides detailed images of the arterial system 
 
Detection of intrasellar aneurysms 
 
Delineation of cranial nerves in their cavernous 
sinus segment 
 
 
(65) 
 
 
(66) 
Magnetic 
Resonance 
Elastography (MRE) 
 
Measures the propagation of shear waves 
through tissue of interest to provide an estimate 
of stiffness 
 
Inform surgical planning by estimating whether a 
PA is likely to be soft (and suckable), or 
intermediate or firm (requiring curettage for 
resection) 
 
(67) 
Magnetic 
Resonance 
Spectroscopy 
(MRA) 
 
Provides information on metabolic function 
through the measurement of different 
metabolites (e.g. acetylaspartate, choline, 
creatine) 
 
 
Differentiation of PA from normal gland 
 
Differential diagnosis of suprasellar lesions 
 
Predicting response of somatotroph tumours to 
SSA therapy 
 
(68) 
 
 
(69,70) 
 
 
(71) 
 
Balanced steady 
state free 
precession (e.g. 
Constructive 
Interference in 
Steady State, CISS; 
Fast Imaging 
Employing Steady-
state Acquisition 
Cycled phases, 
FIESTA-C) 
 
Image contrast determined by T2/T1 ratio of the 
tissue; in practice, heavily water weighted (good 
contrast between CSF and other structures) but 
also sensitive to contrast enhancement 
Improved detection of adenoma in Cushing 
disease 
 
Improved evaluation of cavernous sinus invasion  
 
Prediction of adenoma consistency 
 
Improved delineation of optic nerves and chiasm 
in large pituitary tumors 
 
 
(72) 
 
 
(72) 
 
(73) 
 
(74) 
 
Fluid Attenuation 
Inversion Recovery 
(FLAIR) 
 
An inversion recovery sequence with a long 
inversion time that removes signal from the CSF 
which is therefore dark rather than bright as 
would normally be seen on T2 sequences 
In Cushing disease, delayed contrast washout 
from a corticotroph microadenoma may be 
detected as FLAIR hyperintensity 
(75) 
 
Key: PA, pituitary adenoma; SSA, somatostatin analogue therapy 
  
Figure legends 
 
Fig. 1 Normal pituitary MRI. a-d Spin Echo (SE) T1 weighted coronal and sagittal sequences 
(pre- and post-gadolinium enhancement). e,f Fast Spin Echo (FSE) T2 weighted coronal and 
axial sequences. Key: Gad, gadolinium; ic-ICA, intracavernous segment of the internal carotid 
artery; Inf, infundibulum; OC, optic chiasm; PP, posterior pituitary gland; sc-ICA, 
supracavernous segment of the internal carotid artery; SpS, sphenoid sinus. 
 
Fig. 2 Spectrum of pituitary adenomas. a Left-sided microadenoma exhibiting delayed 
contrast enhancement (yellow arrow). b macroadenoma, displacing the pituitary stalk and 
normal remaining gland to the left (white arrow); there is only limited suprasellar extension 
(without compression of the optic chiasm), but clear extension in to the right cavernous sinus 
(yellow arrow). c macroadenoma with marked suprasellar extension compressing the optic 
chiasm (left>right) (dotted yellow arrows) and right parasellar extension (yellow arrow). d 
macroadenoma with suprasellar extension resulting in compression of the optic chiasm 
(dotted yellow arrows) and left parasellar extension (yellow arrow) – Knosp grade 3A (white 
dashed line); the remaining normal gland is seen on the right/superiorly (white arrow). Key: 
Gad, gadolinium; T1 SE, T1 weighted Spin Echo MRI. 
 
Fig. 3 Pituitary CT. a,b Macroprolactinoma with extensive right parasellar and suprasellar 
extension, and involvement of the skull base (yellow arrows); the position of the optic chiasm 
(yellow dotted arrows) and infundibulum (white arrow) are shown. c Intrasellar calcification 
(yellow arrows) in a patient with a thyrotroph adenoma.  
 
Fig. 4 Confirmation of suspected microprolactinoma using 11C-methionine PET. a 
Indeterminate coronal T1 weighted gadolinium enhanced SE MRI in a 22-year-old female with 
bilateral galactorrhoea, secondary amenorrhoea and moderate hyperprolactinaemia (PRL 3.8 
´ upper limit of normal), confounded by antipsychotic medication usage. b,c Post-gadolinium 
FSPGR MRI in coronal and axial planes identifies a possible right-sided microadenoma 
(yellow arrows). d,e  11C-methionine PET/CT coregistered with FSPGR MRI confirms the site 
of the suspected microprolactinoma (yellow arrows). Key: FSPGR, Fast Spoiled Gradient 
Recalled Echo; Gad, gadolinium; PRL, prolactin; SE, Spin Echo. 
 
Fig. 5 Confirmation of site of suspected residual somatotroph adenoma using 11C-methionine 
PET. a T1 weighted gadolinium enhanced SE MRI in a 50-year-old female with persistent 
acromegaly following transsphenoidal surgery (IGF-1 1.9 ´ upper limit of normal); poorly 
enhancing tissue can be seen medial and inferior to the right cavernous sinus (yellow arrows), 
with normal enhancing tissue on the left of the sella (white arrow). b,c Post-gadolinium FSPGR 
MRI in coronal and axial planes confirms an area of poorly enhancing tissue on the right of 
the sella possibly extending in to the right cavernous sinus (yellow arrows). d,e  11C-
methionine PET/CT coregistered with FSPGR MRI demonstrates focal tracer uptake in the 
right side of the sella, but without cavernous sinus extension (yellow arrows); note low level 
tracer uptake is also seen in the residual normal pituitary tissue (white arrow). Key: FSPGR, 
Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; IGF-1, insulin-like growth factor 1; SE, 
Spin Echo. 
 
Fig. 6 Identification of a left-sided corticotroph adenoma using 11C-methionine PET. a 
Indeterminate T1 weighted gadolinium enhanced SE MRI in a 32-year-old female with 
Cushing disease; there is minor inferior deviation of the floor of the sella on the left (yellow 
arrow), but no clear adenoma is seen. b bilateral inferior petrosal sinus sampling shows clear 
central:peripheral (>245:1 at 3 min) and right:left (>145:1 at 3 min) ACTH (ng/L) gradients 
following injection of 100 mcg human CRH c,d Post-gadolinium FSPGR MRI in coronal and 
axial planes fails to identify a definite adenoma. d,e  11C-methionine PET/CT coregistered with 
FSPGR MRI demonstrates focal tracer uptake in the left side of the gland (yellow arrows); at 
surgery a left-sided corticotroph adenoma was resected with resultant hypocortisolism. Key: 
CRH, corticotrophin releasing hormone; FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, 
gadolinium; L, left; P, peripheral; R, right; SE, Spin Echo.   
 
Fig. 7 Identification of a right-sided thyrotroph adenoma using 11C-methionine PET. a 
Indeterminate T1 weighted gadolinium enhanced SE MRI in a 62-year-old female with a 
biochemically confirmed thyrotropinoma; no clear adenoma is seen. b,c Post-gadolinium 
FSPGR MRI in coronal and axial planes raises suspicion of a possible abnormality on the right 
side of the sella (yellow arrows), but no definite adenoma is seen. d,e  11C-methionine PET/CT 
coregistered with FSPGR MRI demonstrates intense focal tracer uptake in the right side of the 
gland (yellow arrows); at surgery a right-sided thyrotroph adenoma was resected with 
complete resolution of hyperthyroxinaemia secondary to inappropriate TSH secretion. Key: 
FSPGR, Fast Spoiled Gradient Recalled Echo; Gad, gadolinium; SE, Spin Echo.    
 
Fig. 8 Confirmation of the site of recurrent gonadotropinoma using 11C-methionine PET. a T1 
weighted gadolinium enhanced SE MRI in a 50-year-old male with a recurrent functioning 
FSH-secreting pituitary adenoma; abnormal tissue is seen in the left sella region with 
extension in to the sphenoid sinus (yellow arrows), but it is difficult to be sure whether this all 
represents recurrent disease as opposed to post-operative change; the pituitary stalk and 
normal gland are displaced to the right (white arrow) . b,c Post-gadolinium FSPGR MRI in 
coronal and axial planes confirms the findings on SE sequences. d,e  11C-methionine PET/CT 
coregistered with FSPGR MRI demonstrates focal tracer uptake predominantly by tissue in 
the sphenoid sinus with only modest sella uptake (yellow arrows); the normal gland shows low 
level uptake of 11C-methionine (white arrow). Key: FSPGR, Fast Spoiled Gradient Recalled 
Echo; Gad, gadolinium; SE, Spin Echo.    
 
Figure 9: Absent 11C-methionine uptake in a pituitary cyst. a T1 weighted gadolinium 
enhanced SE MRI in a 74-year-old female with an incidentally detected right-sided pituitary 
cystic lesion (yellow arrow); the normal gland is seen on the left (white arrow). b,c Post-
gadolinium FSPGR MRI in coronal and axial planes confirms the findings on SE sequences. 
d,e  11C-methionine PET/CT coregistered with FSPGR MRI demonstrates low level tracer 
uptake only in the normal gland (white arrows). Key: FSPGR, Fast Spoiled Gradient Recalled 
Echo; Gad, gadolinium; SE, Spin Echo.    
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